Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
 
00.250.50.7511.251.51.752+Gutiérre.. (DB RCT)35%0.65 [0.53-0.80]no recov.69/147105/146Improvement, RR [CI]TreatmentControlVeterini29%0.71 [0.41-1.22]viral time15 (n)15 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment34%0.66 [0.55-0.80]69/162105/16134% improvementd'Ettorre87%0.13 [0.01-2.33]death0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]death10/8834/112Li-12%1.12 [0.74-1.69]no disch.30/12341/188Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Tau​2 = 0.12; I​2 = 70.7%Late treatment27%0.73 [0.47-1.15]40/38979/49227% improvementLouca8%0.92 [0.85-0.99]casesImprovement, RR [CI]TreatmentControlAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Tau​2 = 0.17; I​2 = 21.8%PrEP20%0.80 [0.38-1.70]1/294/3120% improvementAll studies21%0.79 [0.67-0.93]110/580188/68421% improvement8 probiotics COVID-19 studiesc19probiotics.com Sep 24, 2021Tau​2 = 0.02; I​2 = 67.5%; Z = 2.79Effect extraction pre-specifiedFavors probioticsFavors control
Database of all probiotics COVID-19 studies. The immune effects of probiotics are strain-specific and studies use different strains. Submit updates/corrections.
Aug 4
Late Zhang et al., Therapeutic Advances in Gastroenterology, doi:10.1177/17562848211035670 (Peer Reviewed) hosp. time, ↓13.6%, p=0.009 Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19
Details   Retrospective 375 patients in China, 179 treated with probiotics (Bifidobacterium, Lactobacillus, and Enterococcus), showing improved clinical outcomes with treatment.
Jun 30
Early Veterini et al., Indian Journal of Forensic Medicine & Toxicology, 15:2 (Peer Reviewed) viral- time, ↓29.0%, p=0.22 Probiotics Intake as Adjunct Therapy for Infected Health-Care with SARS COV-2
Details   Small case control analysis with 15 probiotics patients and 15 contol patients, showing no significant differences. PCR tests were only done weekly. Dosage is unknown. 115/LOE/301.4.2/IX/2020.
Jun 1
Late Meskina et al., Therapeutic Archive, doi:10.26442/00403660.2021.04.200835 (Peer Reviewed) Efficiency of application of sorbed probiotics in complex therapy of pneumonia caused by SARS-CoV-2
Details   RCT 100 pneumonia patients in Russia, showing faster symptom resolution with probiotic treatment (B. bifidum 1).
May 31
PrEP Ahanchian et al., Open Journal of Nursing, doi:10.4236/ojn.2021.115025 (Peer Reviewed) symp. case, ↓73.3%, p=0.35 Synbiotic for Prevention of SARS-Cov2 Infection in High Risk Hospital Staffs: A Randomized Controlled Trial
Details   Small RCT 60 healthcare workers in Iran, showing lower cases with treatment but without statistical significance. Once daily oral synbiotic capsule (Lactocare®) containing 1 billion CFU L. (Lactobacillus) casei, L. rhamnosus, Streptococcu..
May 24
Early Gutiérrez-Castrellón et al., medRxiv, doi:10.1101/2021.05.20.21256954 (Preprint) no recov., ↓34.7%, p<0.0001 Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial
Details   RCT 293 outpatients in Mexico, 147 treated with a probiotic composed of three L. plantarum strains (KABP022, KABP023 and KABP033) and one P. acidilacti strain (KABP021), showing improved recovery with treatment. There were no hospitalizat..
Mar 19
Review Kurian et al., Archives of Medical Research, doi:10.1016/j.arcmed.2021.03.002 (Review) (Peer Reviewed) review Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects
Details   Review of probiotics role in regulating the immune system and use in viral infections, and studies on the association of microbiota with COVID-19 patients. Authors suggest that probiotics supplementation could reduce COVID-19 morbidity an..
Mar 5
Late Li et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107531 (Peer Reviewed) no disch., ↑11.8%, p=0.68 The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients
Details   Retrospective 311 severe condition hospitalized patients in China, 123 treated with probiotics, showing slower viral clearance and recovery with treatment. Authors note that probiotics were able to moderate immunity and decrease the incid..
Feb 13
Review Singh et al., Nutrition Research, doi:10.1016/j.nutres.2020.12.014 (Review) (Peer Reviewed) review Probiotics: A potential immunomodulator in COVID-19 infection management
Details   Review of studies supporting the use of probiotics for respiratory infections and identification of microbial strains potentially beneficial for COVID-19.
Jan 11
Late Ceccarelli et al., Frontiers in Medicine, doi:10.3389/fnut.2020.613928 (Peer Reviewed) death, ↓64.2%, p=0.0002 Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
Details   Retrospective 200 severe condition hospitalized patients in Italy, 88 treated with probiotic Sivomixx, showing lower mortality with treatment.
Dec 15
2020
Review Stavropoulou et al., Frontiers in Nutrition, doi:10.3389/fnut.2020.614986 (Review) (Peer Reviewed) review Probiotics as a Weapon in the Fight Against COVID-19
Details   Review of the potential benefits of probiotics for COVID-19.
Nov 30
2020
PrEP Louca et al., BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2021-000250 (preprint 11/30/20) (Peer Reviewed) cases, ↓8.5%, p=0.03 Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app
Details   Survey analysis of dietary supplements showing probiotic usage associated with lower incidence of COVID-19. These results are for PCR+ cases only, they do not reflect potential benefits for reducing the severity of cases. A number of bias..
Oct 5
2020
Review Olaimat et al., npj Science of Food, doi:10.1038/s41538-020-00078-9 (Review) (Peer Reviewed) review The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19
Details   Review of the immune benefits of probiotics and clinical studies for the preventation and treatment of respiratory infections, recommending trials of probiotics for COVID-19.
Jul 7
2020
Late d'Ettorre et al., Frontiers in Medicine, doi:10.3389/fmed.2020.00389 (Peer Reviewed) death, ↓87.0%, p=0.14 Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
Details   Retrospective 70 hospitalized patients in Italy, 28 treated with probiotic Sivomixx, showing lower risk of respiratory failure and faster recovery with treatment.
May 8
2020
Review Baud et al., Frontiers in Public Health, doi:10.3389/fpubh.2020.00186 (Review) (Peer Reviewed) review Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic
Details   Review of data supporting the use of probiotics for COVID-19 and mechanisms of action.
2015
Meta Hao et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD006895.pub3 (Preprint) (meta analysis) meta-analysis Probiotics for preventing acute upper respiratory tract infections
Details   Meta analysis of 12 RCTs with 3,720 patients showing probiotics reduced acute upper respiratory tract infections.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit